Cargando…
Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
BACKGROUND: As immune checkpoint inhibitors (CPI) are increasingly approved for cancer treatment, hospitalizations related to severe immune-related adverse events (irAE) will increase. Here, we identify patients hospitalized due to irAEs and describe survival outcomes across irAE, CPI, and cancer ty...
Autores principales: | Silverstein, Jordyn, Wright, Francis, Wang, Michelle, Young, Arabella, Kim, Daniel, De Dios, Kimberly, Brondfield, Sam, Quandt, Zoe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546826/ https://www.ncbi.nlm.nih.gov/pubmed/37335906 http://dx.doi.org/10.1093/oncolo/oyad135 |
Ejemplares similares
-
Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019) -
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022) -
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019) -
The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)